

## Rivastigmine

#Cat: NB-64-00383-25mg	Size: 25 mg
#Cat: NB-64-00383-50mg	Size: 50 mg
#Cat: NB-64-00383-100mg	Size: 100mg
#Cat: NB-64-00383-200mg	Size: 200mg
#Cat: NB-64-00383-500mg	Size: 500mg

### Chemical Properties:


CAS No: 123441-03-2

Formula:  $C_{14}H_{22}N_2O_9$

Molecular Weight : 250.34

Appearance : no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



### Biological Description:

<b>Description</b>	Rivastigmine (Exelon) is a Cholinesterase Inhibitor, used for therapy of Alzheimer disease.
<b>Targets (IC50)</b>	Cholinesterase (ChE)
<b>In vitro</b>	Preclinical biochemical studies indicates that rivastigmine has central nervous system selectivity over peripheral inhibition. It ameliorates memory impairment in rats with forebrain lesions. The drug is rapidly absorbed orally, with a bioavailability of 0.355 and low protein binding (40%). Its elimination half-life is less than 2 hours, and it is converted to an inactive metabolite at the site of action, bypassing hepatic metabolic pathways. Its disposition essentially is unaltered in patients with renal or hepatic impairment. It also has dose-dependent effects on AChE inhibition[1].
<b>Cell Research</b>	Chronic toxicity is assessed 7 days after continuous exposure of cells to donepezil or rivastigmine using cell viability and cell esterase activity and the estimated cell numbers as parameters for viability. Culture medium including the tested drugs is changed once after 4 days.(Only for Reference)

### Solubility Information

<b>Solubility</b>	DMSO: 70 mg/mL (279.62 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
-------------------	---

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.9946 mL	19.9728 mL	39.9457 mL
5 mM	0.7989 mL	3.9946 mL	7.9891 mL
10 mM	0.3995 mL	1.9973 mL	3.9946 mL
50 mM	0.0799 mL	0.3995 mL	0.7989 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

## Reference

Jann MW, et al. Pharmacotherapy. 2000, 20(1):1-12.

Abdel-Aal RA, et al. Eur J Pharmacol. 2011, 659(2-3):169-76.

Goldblum D, et al. Ophthalmic Res. 2002, 34(2):97-103.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**  
**This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use**